TriSalus Life Sciences
TLSI
72 hedge funds and large institutions have $230M invested in TriSalus Life Sciences in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 5 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
4% more funds holding
Funds holding: 69 → 72 (+3)
1.99% more ownership
Funds ownership: 91.67% → 93.66% (+2%)
3% more capital invested
Capital invested by funds: $225M → $230M (+$5.88M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$7.64M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.88M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$4.23M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$2.03M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$11.1M |
| 2 |
LA
Linden Advisors
New York
|
-$7.64M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$6.67M |
| 4 |
Millennium Management
New York
|
-$1.41M |
| 5 |
KC
Kryger Capital
London,
United Kingdom
|
-$551K |
TLSI Hedge Fund Activity: Q2 2022 in Review
72 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q2 2022, worth a combined $230M — up 2.6% from $225M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TLSI positions and 5 closed out — a net gain of 3 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $7.64M. The largest seller was Weiss Asset Management, cutting an estimated $11.1M.
- 72 institutional investors held TriSalus Life Sciences (TLSI) as of Q2 2022, up from 69 in Q1 2022.
- Funds reported $230M of TriSalus Life Sciences stock for Q2 2022, up 2.6% quarter-over-quarter.
- 8 funds opened new TriSalus Life Sciences positions in Q2 2022 and 5 closed out, a net change of +3 holders.
- The largest TriSalus Life Sciences buyer in Q2 2022 was Bank of Montreal, an estimated $7.64M added.
- The largest TriSalus Life Sciences seller in Q2 2022 was Weiss Asset Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2022.